Study links Blood pressure drugs to cancer
June 15th, 2010 - 7:57 pm ICT by Aishwarya BhattNew York, Jun 15 (THAINDIAN NEWS) A new study by Lancet Oncology medical journal says there is a modest increased risk of cancer in people who use certain classes of blood pressure drugs.
The research results were published online on Sunday and the results said that due to limited data on the research, it is impossible to currently calculate the exact risk of cancer in the drugs.
The group of drugs identified with cancer includes high-class drugs manufactured by companies like Boehringer Ingelheim GmbH, Merck & Co. Novartis AG. The drugs include Cozaar from Merck & Co., Diovan from Novartis AG and Micardis from Boerhinger Ingelheim. These types of drugs are called angiotensin-receptor blockers (ARB’s). The drugs are used to treat heart failure, blood pressure and reduction of cardiovascular disease.
However some of the manufacturers of these drugs have questioned the study. Boerhinger Ingelheim says they have undertaken extensive and comprehensive internal safety data analysis on the drugs and that data available to the company does not support the study at all. The company said that they have carried out clinical trials in more than 50,000 patients and they say the safety data available points to positive profile in the patients.
Sales of ARB’s worldwide are estimated at over $100 billion annually and last year’s figures showed that Novartis’s Diovan sold more than $6billion.
- Common Blood Pressure Drugs May Amplify The Risk Of Cancer - Jun 15, 2010
- Combination ACE inhibitor therapy raises risk of kidney failure, death - Mar 22, 2011
- Blood pressure medications show higher cancer risk: Study - Jun 14, 2010
- Blood Pressure Drugs Increase Cancer Risk, Study Reveals - Jun 15, 2010
- FDA says that Female Viagra falls short - Jun 17, 2010
- FDA Not Impressed By The First 'Female Viagra' - Jun 17, 2010
- BP drug could harm stroke patients - Feb 13, 2011
- FDA dissociates Fosamax from fractures - Mar 12, 2010
- 'Female viagra' fails to win approval - Jun 19, 2010
- Cellphone that monitors heart problems and informs doctor - Aug 18, 2010
- Ruia Group to acquire two European firms - May 11, 2011
- FDA rejects combo cholesterol drug - Mar 07, 2012
- Anti-hypertensive drug improves multiple sclerosis-related brain inflammation - Jul 29, 2010
- Patients receiving dialysis 'at higher risk for sudden cardiac death' - Nov 15, 2010
- BP drug not tied to death risk among heart patients - Apr 11, 2012
Tags: arb, blood pressure drugs, boehringer ingelheim gmbh, boerhinger, cardiovascular disease, co diovan, cozaar, diovan, heart failure, internal safety, lancet oncology, medical journal, merck, merck co, micardis, novartis, novartis ag, receptor blockers, safety data, types of drugs